Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/124235
Title: Genomics And Susceptibility Profiles Of Extensively Drug-resistant Pseudomonas Aeruginosa Isolates From Spain
Author: Barrio Tofiño, Ester
López Causapé, Carla
Cabot, Gabriel
Rivera, Alba
Benito Hernández, M. Natividad de
Segura, Concepción
Montero, María Milagro
Sorli, Luisa
Tubau, Fe
Gómez-Zorrilla Martín, Silvia
Tormo, Nuria
Durá Navarro, Raquel
Viedma, Esther
Resino Foz, Elena
Fernández Martínez, Marta
González Rico, Claudia
Alejo-Cancho, Izaskun
Martínez, José Antonio (Martínez Martínez)
Labayru Echverria, Cristina
Dueñas, Carlos J.
Ayestaran, Ignacio
Zamorano, Laura
Martínez Martínez, Luis
Horcajada Gallego, Juan Pablo
Oliver, Antonio
Keywords: Epidemiologia molecular
Pseudomonas
Molecular epidemiology
Issue Date: 1-Nov-2017
Publisher: American Society for Microbiology
Abstract: This study assessed the molecular epidemiology, resistance mechanisms, and susceptibility profiles of a collection of 150 extensively drug-resistant (XDR) Pseudomonas aeruginosa clinical isolates obtained from a 2015 Spanish multicenter study, with a particular focus on resistome analysis in relation to ceftolozane-tazobactam susceptibility. Broth microdilution MICs revealed that nearly all (> 95%) of the isolates were nonsusceptible to piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, imipenem, meropenem, and ciprofloxacin. Most of them were also resistant to tobramycin (77%), whereas nonsusceptibility rates were lower for ceftolozane-tazobactam (31%), amikacin (7%), and colistin (2%). Pulsed-field gel electrophoresis-multilocus sequence typing (PFGE-MLST) analysis revealed that nearly all of the isolates belonged to previously described high-risk clones. Sequence type 175 (ST175) was detected in all 9 participating hospitals and accounted for 68% (n = 101) of the XDR isolates, distantly followed by ST244 (n = 16), ST253 (n = 12), ST235 (n = 8), and ST111 (n = 2), which were detected only in 1 to 2 hospitals. Through phenotypic and molecular methods, the presence of horizontally acquired carbapenemases was detected in 21% of the isolates, mostly VIM (17%) and GES enzymes (4%). At least two representative isolates from each clone and hospital (n = 44) were fully sequenced on an illumina MiSeq. Classical mutational mechanisms, such as those leading to the overexpression of the beta-lactamase AmpC or efflux pumps, OprD inactivation, and/or quinolone resistance-determining regions (QRDR) mutations, were confirmed in most isolates and correlated well with the resistance phenotypes in the absence of horizontally acquired determinants. Ceftolozane-tazobactam resistance was not detected in carbapenemase-negative isolates, in agreement with sequencing data showing the absence of ampC mutations. The unique set of mutations responsible for the XDR phenotype of ST175 clone documented 7 years earlier were found to be conserved, denoting the long-term persistence of this specific XDR lineage in Spanish hospitals. Finally, other potentially relevant mutations were evidenced, including those in penicillin-binding protein 3 (PBP3), which is involved in beta-lactam (including ceftolozane-tazobactam) resistance, and FusA1, which is linked to aminoglycoside resistance.
Note: Reproducció del document publicat a: https://doi.org/10.1128/AAC.01589-17
It is part of: Antimicrobial Agents And Chemotherapy, 2017, vol. 61, num. 11
URI: http://hdl.handle.net/2445/124235
Related resource: https://doi.org/10.1128/AAC.01589-17
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
del Barrio-TofinoE.pdf1.38 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.